Antibiotic Resistance Markets - Therapeutics. By Pathogen and Therapy Type. With Situation Analysis, Executive and Investor Guides. 2025 to 2029

Antimicrobial Resistance is creating new kinds of infections and "superbugs" that are resistant to current antibiotic medicines. New technologies (and new drugs) are under development to capture this growing market. We have identified the 6 Key Large Opportunities in this space and developed market forecasts. We have looked at the technology picture too, giving you, plain language understanding of the different ways pathogens, and infections, can be treated, including an explanation of the key role diagnostics will play. This is a market with a lot of players, there are over 100 biotechnology companies profiled in the report. And we summarize what technologies they are using.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

1. Market Guides

1.1. Strategic Situation Analysis
1.2. Guide for Executives and Business Development Staff
1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

2.1. Antimicrobial Resistance
2.2. Defining the Opportunity
- 2.2.1. Revenue Market Size
2.3. Methodology
- 2.3.1. Methodology
- 2.3.2. Sources
- 2.3.3. Authors
2.4. U.S. Antibiotic Markets - Perspective
- 2.4.1. U.S. Outpatient Use of Antibiotics
- 2.4.2. U.S. Pharmaceutical Spending

3. Overview of a Dynamic Market

3.1. Market Players - Roles & Impacts
- 3.1.1. Drug manufacturers - Larger/pharmaceutical
- 3.1.2. Drug manufacturers - Generic
- 3.1.3. Contract Research and Manufacturing
- 3.1.4. In Vitro Diagnostics Industry
- 3.1.5. Drug Marketing Companies
- 3.1.6. Biotechnology Companies
- 3.1.7. Regulatory Bodies
3.2. Understanding Antimicrobial Resistance
- 3.2.1. What is Antimicrobial Resistance (AMR)
- 3.2.2. Bacteria and Other Microbes
- 3.2.3. The History of Antibiotics
- 3.2.4. The Role of Animal Husbandry
- 3.2.5. The Implications of Horizontal Transfer
- 3.2.6. The Threat of AMR
3.3. The Changing Road to New Antibiotics & Technologies
3.4. The Key Role of Diagnostics in AMR

4. The Market Opportunity of AMR

4.1. The Key Large Market Opportunities in AMR
- 4.1.1. Streptococcus Pneumoniae (DRSP)
- 4.1.2. Campylobacter (DRC)
- 4.1.3. Clostridium Difficile (CD)
- 4.1.4. Staphylococcus aureus (MRSA)
- 4.1.5. Neisseria gonorrhoeae (DRNG)
- 4.1.6. Salmonella (DRNTS)
4.2. Therapeutic Technology Development Opportunities
- 4.2.1. Using Viruses Against Bacteria
- 4.2.2. Hydrolytic Enzymes Join the Fight
- 4.2.3. Antibodies
- 4.2.4. Vaccines
- 4.2.5. Probiotic Technology
- 4.2.6. Peptides vs. Pathogens
- 4.2.7. Mining Obsolete Science
- 4.2.8. CRISPR Antibiotics

5. Antibiotic Resistance Recent Developments

5.1.1. Recent Developments - Importance and How to Use This Section
5.1.2. Importance of These Developments
5.1.3. How to Use This Section
5.2. Drug-free method to combat AMR
5.3. Superbug linked to a common antibiotic
5.4. Building evidence for the use of bacteriophages against AMR
5.5. Phage Therapies to Crush Antimicrobial Resistance
5.6. Bacteriophage May Combat AMR
5.7. Shionogi to Acquire Qpex Biopharma
5.8. Adaptive Phage Therapeutics to Fight Antibiotic Resistance
5.9. Smartbax to create next-generation antibiotics
5.10. Startup Solu raises Euro-1M to combat AMR
5.11. Akthelia Pharma and University of Iceland to Combat AMR
5.12. WHO warns of too few new Antibiotics
5.13. Bactobio Raises Pound-6 Million To Discover Novel Antimicrobials
5.14. AMR triggers race to develop phages
5.15. AMR Pandemic Overlooked
5.16. New resistance-busting antibiotic combination
5.17. CDC Awards $22M to Combat Antimicrobial Resistance
5.18. Antibiotic resistance outwitted by supercomputers
5.19. STIs Reach Record Highs
5.20. New research using nanoparticles to bolster waning antibiotics
5.21. OpGen Receives FDA Clearance for AMR Panel
5.22. CDC Updates STI Diagnosis, Treatment Guidelines
5.23. Positive associations between AM use in animals and AMR in humans
5.24. PEW Antibiotic Pipeline Findings

6. Key Biotechnology Companies and Their Technology

6.1. Melinta Therapeutics
6.2. Arsanis
6.3. Phage Technologies S.A
6.4. Westway Health
6.5. Tetraphase Pharmaceuticals
6.6. BioVersys GmbH
6.7. Nabriva Therapeutics
6.8. Macrolide Pharmaceuticals
6.9. Nemesis Bioscience
6.10. C3J Therapeutics, Inc.
6.11. EpiBiome
6.12. discuva
6.13. SmartPhage
6.14. AmpliPhi Biosciences
6.15. Pherecydes Pharma
6.16. Micreos
6.17. Procarta Biosystems
6.18. Lumavita
6.19. Madam Therapeutics
6.20. Priaxon
6.21. Biolytx Pharmaceuticals
6.22. AntibioTx
6.23. Xellia Pharmaceutials
6.24. Paratek Pharmaceuticals
6.25. Synereca Pharmaceuticals
6.26. Allecra Therapeutics
6.27. Fixed Phage
6.28. Enanta Pharmaceuticals, Inc.
6.29. Demuris
6.30. Prommune
6.31. Biosergen
6.32. Innovation Pharmaceuticals
6.33. Aviragen Therapeutics
6.34. Achillion Pharmaceuticals
6.35. ImmunNovative Developments, S.L.
6.36. Achaogen, Inc
6.37. SelectX Pharmaceuticals, Inc.
6.38. TaiGen Biotechnology Co., Ltd.
6.39. Theravance Biopharma
6.40. Abbvie
6.41. KYORIN Pharmaceutical Co.,Ltd.
6.42. Iterum Therapeutics Limited
6.43. Forge Therapeutics
6.44. Alopexx Vaccine LLC
6.45. Integrated Biotherapeutics
6.46. Hennepin Life Sciences
6.47. Fedora Pharmaceuticals Inc.
6.48. Contrafect Corporation
6.49. Basilea Pharmaceutica Ltd.
6.50. AiCuris
6.51. RedHill Biopharma
6.52. Redx Pharma Plc/ Redx Anti Infectives Ltd.
6.53. ABAC Therapeutics
6.54. Alaxia SAS
6.55. Antabio S.A.S
6.56. Auspherix Ltd
6.57. BioFilm Pharma
6.58. Centauri Therapeutics Ltd
6.59. Combioxin SA
6.60. Da Volterra
6.61. Debiopharm International SA
6.62. Deinobiotics/Deinove
6.63. Destiny Pharma plc
6.64. Eligo Bioscience
6.65. Helperby Therapeutics Ltd
6.66. Karveel Pharmaceuticals
6.67. MaaT Pharma
6.68. Motif BioSciences, Inc / Motif Bio PLC
6.69. Mutabilis SAS
6.70. Neem Biotech Ltd
6.71. Northern Antibiotics Oy (Ltd)
6.72. Nosopharm
6.73. NovaBiotics Ltd
6.74. Phico Therapeutics Ltd
6.75. Polyphor Ltd
6.76. QureTech Bio AB
6.77. SetLance srl
6.78. Ultupharma AB
6.79. Vaxdyn
6.80. Vibiosphen
6.81. Bioaster
6.82. Vivexia
6.83. KBP Biosciences
6.84. Absynth Biologics
6.85. Spero Therapeutics
6.86. Merck
6.87. Symphogen
6.88. Warp Drive Bio
6.89. Johnson & Johnson (Janssen)
6.90. Pfizer
6.91. Allergan
6.92. GlaxoSmithKline
6.93. Novartis
6.94. Gilead Sciences
6.95. AstraZeneca
6.96. Sanofi
6.97. Shionogi Inc.
6.98. Cipla
6.99. DSM Sinochem Pharmaceuticals
6.100. Wockhardt Ltd.
6.101. VenatoRx Pharmaceuticals
6.102. MicuRx
6.103. Entasis Therapeutics
6.104. Merlion Pharmaceuticals
6.105. Aridis Pharmaceuticals Inc.
6.106. The Therapeutics Race - Summary of Companies Research Areas

7. Global Market Size

7.1. Global Market by Country
7.2. Global Market by Pathogen
7.3. Global Market by Technology

8. Market Sizes by Pathogen

8.1. DRSP Market
8.2. DRC Market
8.3. CD Market
8.4. MRSA Market
8.5. DRNG Market
8.6. DRNTS Market
8.7. Other Pathogen Market

9. Market Sizes by Technology

9.1. Antibiotics Market
9.2. Phage Market
9.3. Pep/Lys Market
9.4. Antibodies Market
9.5. Vaccine Market
9.6. Other Technology Market

10. The Future of AMR

11. Appendices

11.1. United States Medicare System: Top Selling Drugs

Table of Tables

Table 1: USA - Outpatient Use of Antibiotics by Class
Table 2: USA - Outpatient Use of Antibiotics Top 5
Table 3: Market Players by Type
Table 4: Known Human Pathogenic Diseases
Table 5: The Key Market Opportunities
Table 6 - Market Potential DRSP Therapeutic
Table 7 - Market Potential DRC Therapeutic
Table 8: Eight Technologies under development
Table 9: Antibodies Approved for Infectious Disease Treatment
Table 10: Therapeutic Technology Research - # of Companies
Table 11: Global Market by Country
Table 12: Global Market by Pathogen
Table 13: Global Market by Technology
Table 14: DRSP Segment by Country
Table 15: DRC Segment by Country
Table 16: CD Segment by Country
Table 17: MRSA Segment by Country
Table 18: DRNG Segment by Country
Table 19: DRNTS Segment by Country
Table 20: Other Pathogen Segment by Country
Table 21: Antibiotics Segment by Country
Table 22: Phage Segment by Country
Table 23: Pep/Lys Segment by Country
Table 24: Antibodies Segment by Country
Table 25: Vaccine Segment by Country
Table 26: Other Technology Segment by Country
Table 27: Top Selling Drugs

Table of Figures

Figure 1: Pharmaceutical Spending Trends
Figure 2: AMR and Antibiotic Introduction
Figure 3: The Death Toll of AMR
Figure 4: Phage T4 Anatomy and Infection Cycle
Figure 5: Key Global Markets
Figure 6: Pathogen Share by Year
Figure 7: Pathogen Segment Growth Rates
Figure 8: Segment Share Shifts
Figure 9: Market Share Start Year
Figure 10: Market Share End Year
Figure 11: Technology Share by Year
Figure 12: Pathogen Segment Growth Rates
Figure 13: Segment Share Shifts
Figure 14: Market Share Start Year
Figure 15: Market Share End Year
Figure 16: DRSP vs. Total Market Growth
Figure 17: DRC vs. Total Market Growth
Figure 18: CD vs. Total Market Growth
Figure 19: MRSA vs. Total Market Growth
Figure 20: DRNG vs. Total Market Growth
Figure 21: DRNTS vs. Total Market Growth
Figure 22: Other Pathogen vs. Total Market Growth
Figure 23: Antibiotics vs. Total Market Growth
Figure 24: Phage vs. Total Market Growth
Figure 25: Pep/Lys vs. Total Market Growth
Figure 26: Antibodies vs. Total Market Growth
Figure 27: Vaccine vs. Total Market Growth
Figure 28: Other Technology vs. Total Market Growth